Do I Need an EU Authorized Representative to Sell in Europe?

# Do I Need an EU Authorized Representative to Sell in Europe? A Guide for Medical Device Manufacturers For medical device manufacturers based outside the European Union, accessing the vast European market requires navigating a specific set of regulatory requirements. One of the most fundamental of these is the appointment of an EU Authorized Representative (AR). This entity serves as a manufacturer's legal representative within the EU, acting as the primary point of contact for national Competent Authorities and Notified Bodies. The requirement for a local representative is not unique to medical devices. Other regulations, like the Carbon Border Adjustment Mechanism (CBAM), also mandate in-market representation. However, the responsibilities, liabilities, and cost drivers for an EU AR under the Medical Device Regulation (MDR) are fundamentally different. While a CBAM declarant’s role is driven by trade volume and emissions data, an EU AR’s obligations are intrinsically tied to the medical device's risk class, technical complexity, and post-market safety. Understanding this role is the first critical step for any non-EU manufacturer planning to place a device on the European market. ## Key Points * **Mandatory Requirement:** If you are a medical device manufacturer located outside the European Union, you are legally required to appoint an EU Authorized Representative to place your device on the EU market. * **Legal Liability:** Under the MDR (EU) 2017/745, the EU AR is jointly and severally liable with the manufacturer for defective devices. This shared risk makes the selection of a qualified AR a critical business decision. * **Core Responsibilities:** The AR is not just a mailing address. Their duties include verifying the manufacturer’s Declaration of Conformity and technical documentation, cooperating with Competent Authorities on request, and playing a key role in vigilance and incident reporting. * **Not a Distributor:** The role of the AR is strictly regulatory. While a distributor may sometimes also act as an AR, their commercial interests can conflict with the AR’s compliance obligations. It is often recommended to keep these roles separate. * **The Mandate is Key:** The relationship between the manufacturer and the AR must be formalized in a detailed written mandate or service agreement that explicitly outlines all duties, responsibilities, and procedures. * **Varying Service Models:** AR services range from basic "mailbox" functions to comprehensive compliance partnerships. The cost and level of support reflect this spectrum, and manufacturers must choose a model that aligns with their device's risk profile and their own internal resources. ## What is an EU Authorized Representative? An EU Authorized Representative is a natural or legal person established within the European Union who is explicitly designated by a non-EU manufacturer to act on their behalf in relation to specific tasks required under the MDR. The legal basis and responsibilities for the AR are detailed in **Article 11 of the MDR (EU) 2017/745**. The AR serves two primary functions: 1. **A Liaison:** They are the official point of contact for EU Competent Authorities (e.g., Germany's BfArM, France's ANSM) and Notified Bodies regarding the manufacturer's compliance. 2. **A Gatekeeper:** They have a legal obligation to ensure the manufacturer has met key regulatory requirements *before* the device is placed on the market and to support post-market surveillance activities. The name and address of the EU AR must appear on the device's labeling, packaging, and Instructions for Use (IFU), making them clearly identifiable to both regulators and end-users. ## Core Responsibilities of the EU Authorized Representative The responsibilities of the EU AR are extensive and legally binding. A manufacturer should ensure their AR has the resources, expertise, and procedures in place to fulfill these duties. ### Key Duties as per MDR Article 11: * **Documentation Verification:** The AR must verify that the EU Declaration of Conformity and the technical documentation have been drawn up and that the manufacturer has completed the appropriate conformity assessment procedure. * **Document Availability:** The AR must keep a copy of the technical documentation, the Declaration of Conformity, and any relevant certificates (including amendments and supplements) available for inspection by Competent Authorities for the required retention period (at least 10 years after the last device has been placed on the market, or 15 years for implantable devices). * **Registration Support:** The AR verifies that the manufacturer has correctly registered the device and their own company details in the EUDAMED database as required by Article 29. * **Cooperation with Authorities:** The AR must fully cooperate with Competent Authorities on any request, providing samples, information, and documentation necessary to demonstrate the conformity of a device. They must forward any requests from authorities to the manufacturer and ensure the authority receives a response. * **Vigilance and Post-Market Surveillance (PMS):** This is one ofthe most critical functions. The AR must be immediately informed by the manufacturer about any complaints, field safety corrective actions (FSCAs), and serious incidents. They play an active role in reporting these events to the relevant Competent Authorities according to the strict timelines defined in the MDR. * **Termination of Agreement:** The AR has the right and obligation to terminate the mandate if the manufacturer acts contrary to their obligations under the MDR. They must inform the relevant Competent Authority and, if applicable, the Notified Body of this termination. ## How to Select the Right EU AR Partner Choosing an EU AR is not a simple procurement task; it is the selection of a long-term regulatory partner. The shared liability model under the MDR means that a failure by your AR can have direct and severe consequences for your business. ### Scenario 1: The "Mailbox" AR Model A manufacturer of a Class I non-sterile device might be tempted to choose a low-cost AR provider that offers a basic "address-only" service. * **What it Looks Like:** This service provides the minimum legal requirement: a name and address in the EU. Communication is often reactive, and the AR may have limited regulatory expertise or infrastructure. * **What Regulators Will Scrutinize:** If a complaint or inspection occurs, will this AR be able to produce technical documentation promptly? Do they have a documented procedure for handling vigilance reports? A low-cost provider may not have the robust Quality Management System (QMS) expected by authorities. * **Risks:** The manufacturer bears almost all the practical compliance burden. If the AR fails to transmit an urgent request from a Competent Authority or mishandles a vigilance report, the manufacturer is still held responsible. This model offers minimal support and can create significant compliance gaps. ### Scenario 2: The "Compliance Partner" AR Model A manufacturer of a Class IIb active implantable device or a complex SaMD product should seek an AR that acts as a true compliance partner. * **What it Looks Like:** This is a full-service provider with deep regulatory expertise, often specific to the device type. They proactively review key documentation, have a certified QMS (e.g., ISO 13485), and offer strategic guidance. Their fees are higher, reflecting their deeper involvement and assumption of risk. * **What Regulators Will Scrutinize:** Authorities expect a professional and knowledgeable interaction. A partner-level AR will have established communication channels, robust and audited procedures for documentation control and vigilance, and experienced staff who can manage inspections and requests effectively. * **Benefits:** This model significantly reduces regulatory risk for the manufacturer. The AR acts as an extension of the manufacturer's own quality and regulatory team, providing a crucial layer of review and local expertise. They help ensure that communication with authorities is handled professionally and in compliance with all MDR requirements. ## Strategic Considerations and Questions to Ask a Potential EU AR Before signing a mandate, conduct thorough due diligence. Here is a checklist of questions to ask potential EU Authorized Representatives: **1. Experience and Expertise:** * What is your experience with our device class and technology? * Can you provide references from other non-EU manufacturers? * Who on your team will be responsible for our account, and what are their qualifications? **2. Quality Management System (QMS):** * Do you have a QMS in place? Is it certified to ISO 13485? * Can we review your procedures for handling document requests, complaints, and vigilance reporting? **3. Liability and Insurance:** * How is your professional liability insurance structured? * Does your insurance cover regulatory actions related to medical devices? What are the coverage limits? **4. Service Agreement and Mandate:** * Can we review a template of your AR mandate? * What are the precise services included in your fee? What is considered out-of-scope? * What are the procedures and costs for transferring the AR service to another provider if needed? **5. Communication and Reporting:** * What is your standard procedure for notifying us of a communication from a Competent Authority? * How do you manage and track vigilance reporting deadlines? ## How Does the EU AR Role Compare to the U.S. Agent? While both roles serve as a local point of contact for foreign manufacturers, their legal responsibilities differ. The U.S. Agent, as defined under U.S. regulations like **21 CFR Part 807**, primarily serves as a communication link between the FDA and the foreign establishment. Their role is largely administrative. In contrast, the EU AR's role under the MDR is far more substantive, involving active verification of compliance documentation and, most importantly, sharing legal liability for the device. While **FDA guidance documents** outline the responsibilities for U.S. Agents, the concept of "joint and several liability" makes the EU AR a much more integrated and risk-bearing partner. ## Finding and Comparing EU Authorized Representative (MDR) Providers Finding a qualified and trustworthy EU AR is critical for market success and long-term compliance. When evaluating potential partners, manufacturers should look for a combination of regulatory expertise, a robust QMS, transparent pricing, and a strong track record with devices of a similar risk class. Comparing multiple providers allows you to assess the market, understand different service models, and find the best fit for your company’s needs and budget. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/eu_ar) and request quotes for free. ## Key EU References When discussing requirements with a potential AR, referencing the official sources is crucial. The key documents governing the EU AR role include: * **EU Medical Device Regulation (MDR) (EU) 2017/745:** Article 11 is the primary source defining the mandate, obligations, and liability of the Authorized Representative. * **MDCG 2022-16:** Guidance from the Medical Device Coordination Group (MDCG) on the application of requirements concerning the person responsible for regulatory compliance (PRRC), which has interactions with the AR role. * **Guidance documents from Competent Authorities:** Many national authorities publish guidance that clarifies their expectations for ARs operating in their jurisdiction. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*